评估Nelipepimut-S治疗乳腺癌：关于新出现数据的简短报告。
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data.
作者信息
Dillon Patrick M, Brenin Christiana M, Slingluff Craig L
机构信息
University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA.
University of Virginia, Department of Surgery, Charlottesville, VA 22908, USA.
出版信息
Breast Cancer (Dove Med Press). 2020 Apr 3;12:69-75. doi: 10.2147/BCTT.S224758. eCollection 2020.
Abstract
Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.
摘要
用于治疗和预防癌症的疫苗疗法疗效一般，其疗效因肿瘤类型、疫苗类型、佐剂以及研究的临床环境不同而有很大差异。在过去二十年中，人们对多种用于乳腺癌的肽疫苗进行了研究。目前用于人体的领先肽疫苗是一种基于HER2的疫苗，名为Nelipepimut-S，它在某些情况下已显示出免疫活性和有前景的临床活性。这篇综述涵盖了这种新型肽疫苗针对HER2扩增和非扩增乳腺癌的研发情况。
相似文献
1
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data.评估Nelipepimut-S治疗乳腺癌：关于新出现数据的简短报告。
Breast Cancer (Dove Med Press). 2020 Apr 3;12:69-75. doi: 10.2147/BCTT.S224758. eCollection 2020.
2
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.HER2肽奈立匹穆-S（E75）疫苗（NeuVax™）用于有复发风险的乳腺癌患者：免疫数据与临床反应的相关性
Immunotherapy. 2014;6(5):519-31. doi: 10.2217/imt.14.22.
3
The development and use of the E75 (HER2 369-377) peptide vaccine.E75（HER2 369-377）肽疫苗的研发与应用。
Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.
4
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.Nelipepimut-S+GM-CSF 和曲妥珠单抗对比单用曲妥珠单抗用于预防低表达 HER2 肿瘤乳腺癌患者复发的随机 II 期试验的初步安全性分析。
Clin Immunol. 2019 Apr;201:48-54. doi: 10.1016/j.clim.2019.02.011. Epub 2019 Feb 25.
5
Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer.一项将曲妥珠单抗与肽疫苗联合使用的随机试验结果表明，HER2靶向治疗在三阴性乳腺癌中具有一定作用。
Oncotarget. 2021 Nov 9;12(23):2318-2319. doi: 10.18632/oncotarget.27998.
6
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.尼利帕木单抗疫苗预防乳腺癌复发的疗效和安全性分析：一项随机、多中心、III 期临床试验。
Clin Cancer Res. 2019 Jul 15;25(14):4248-4254. doi: 10.1158/1078-0432.CCR-18-2867. Epub 2019 Apr 29.
7
HER2-Based Immunotherapy for Breast Cancer.基于 HER2 的乳腺癌免疫治疗。
Cancer Biother Radiopharm. 2018 Jun;33(5):169-175. doi: 10.1089/cbr.2017.2327. Epub 2018 Jun 6.
8
MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.载有 P5 HER2/neu 衍生肽脉冲 PADRE 的 MPL 纳米脂质体疫苗作为一种有效的疫苗，在乳腺癌 TUBO 模型的小鼠中。
J Control Release. 2019 Jun 10;303:223-236. doi: 10.1016/j.jconrel.2019.04.019. Epub 2019 Apr 15.
9
Developing anti-HER2 vaccines: Breast cancer experience.开发抗 HER2 疫苗：乳腺癌的经验。
Int J Cancer. 2018 Nov 1;143(9):2126-2132. doi: 10.1002/ijc.31551. Epub 2018 May 10.
10
Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.外泌体 pMHC-I 复合物将 T 细胞为基础的疫苗靶向递送至 CTL，在转基因 FVBneuN 和 HLA-A2/HER2 小鼠中引发抗肿瘤免疫，并在无胸腺裸鼠中根除曲妥珠单抗耐药肿瘤。
Breast Cancer Res Treat. 2013 Jul;140(2):273-84. doi: 10.1007/s10549-013-2626-7. Epub 2013 Jul 24.
引用本文的文献
1
Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer.增强免疫反应：针对乳腺癌的微粒疫苗方法
Breast Cancer (Dove Med Press). 2024 Mar 28;16:149-162. doi: 10.2147/BCTT.S441368. eCollection 2024.
2
Novel HER-2 Targeted Therapies in Breast Cancer.乳腺癌中的新型HER-2靶向疗法。
Cancers (Basel). 2023 Dec 23;16(1):87. doi: 10.3390/cancers16010087.
3
Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.基于曲妥珠单抗治疗的HER2阳性乳腺癌复发的基因和免疫特征鉴定。
Breast Cancer Res Treat. 2023 Jun;199(3):603-615. doi: 10.1007/s10549-023-06931-1. Epub 2023 Apr 21.
4
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.乳腺癌中针对HER2的治疗：即将出现的新药与模式
Explor Target Antitumor Ther. 2021;2(2):139-155. doi: 10.37349/etat.2021.00037. Epub 2021 Apr 30.
5
Immunological Landscape of HER-2 Positive Breast Cancer.HER-2阳性乳腺癌的免疫格局
Cancers (Basel). 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167.
6
Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.人表皮生长因子受体 2 阳性乳腺癌的治疗性景观。
Cancer Control. 2022 Jan-Dec;29:10732748221099230. doi: 10.1177/10732748221099230.
7
Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.癌症疫苗的演变——挑战、成就与未来方向
Vaccines (Basel). 2021 May 20;9(5):535. doi: 10.3390/vaccines9050535.
本文引用的文献
1
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.Nelipepimut-S+曲妥珠单抗对比曲妥珠单抗用于预防高风险 HER2 低表达乳腺癌患者复发的随机 IIb 期试验结果。
Clin Cancer Res. 2020 Jun 1;26(11):2515-2523. doi: 10.1158/1078-0432.CCR-19-2741. Epub 2020 Feb 18.
2
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.尼利帕木单抗疫苗预防乳腺癌复发的疗效和安全性分析：一项随机、多中心、III 期临床试验。
Clin Cancer Res. 2019 Jul 15;25(14):4248-4254. doi: 10.1158/1078-0432.CCR-18-2867. Epub 2019 Apr 29.
3
Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis.E75 肽疫苗在乳腺癌患者中的应用：系统评价和荟萃分析。
Eur J Pharmacol. 2018 Jul 15;831:87-93. doi: 10.1016/j.ejphar.2018.05.010. Epub 2018 May 9.
4
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.一项初步研究显示，在早期乳腺癌患者中，一种 9 肽乳腺癌疫苗联合聚肌胞苷酸（poly-ICLC）具有免疫原性。
J Immunother Cancer. 2017 Nov 21;5(1):92. doi: 10.1186/s40425-017-0295-5.
5
A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.携带 E75（一种 HER-2/neu 衍生肽）的纳米脂质体疫苗在小鼠中表现出显著的抗肿瘤活性。
J Drug Target. 2018 Apr;26(4):365-372. doi: 10.1080/1061186X.2017.1387788. Epub 2017 Oct 18.
6
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 DCIS Independent of Route: Results of Randomized Selection Design Trial.树突状细胞疫苗接种增强免疫反应，并独立于途径诱导 HER2 DCIS 消退：随机选择设计试验的结果。
Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13.
7
The development and use of the E75 (HER2 369-377) peptide vaccine.E75（HER2 369-377）肽疫苗的研发与应用。
Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.
8
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.E75（奈培匹莫特-S）疫苗联合加强接种预防高危乳腺癌患者疾病复发的I/II期临床试验最终报告
Ann Oncol. 2014 Sep;25(9):1735-1742. doi: 10.1093/annonc/mdu211. Epub 2014 Jun 6.
9
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.HER-2/neu（E75）疫苗预防高危患者乳腺癌复发的临床试验结果：来自美国军事癌症研究所临床试验组研究 I-01 和 I-02。
Cancer. 2012 May 15;118(10):2594-602. doi: 10.1002/cncr.26574. Epub 2011 Oct 11.
10
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.使用加强针来维持辅助乳腺癌疫苗的临床效果：来自美国军事癌症研究所临床试验组研究 I-01 和 I-02。
Cancer. 2011 Feb 1;117(3):463-71. doi: 10.1002/cncr.25586. Epub 2010 Sep 15.
Zotero 插件